Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes

Table 3 Spearman correlation analyses between PCSK9 and platelet activation makers according to diabetes status

	Whole cohort (n = 1027)		DM (n = 277)		Non-DM (n = 750)
	r	P	r	P	r	P
sP-selectin	0.158	0.015	0.181	0.001	0.141	0.065
sCD40L	0.176	< 0.001	0.279	< 0.001	0.086	0.001
Without prior antiplatelet therapy (n = 897)			n = 225		n = 672
sP-selectin	0.133	0.012	0.216	< 0.001	0.105	0.057
sCD40L	0.219	< 0.001	0.317	< 0.001	0.187	< 0.001

PCSK9 proprotein convertase subtilisin/kexin type 9, DM diabetes mellitus, non-DM non-diabetes mellitus, sP-selectin soluble P-selectin, sCD40L soluble CD40 ligand

ISSN: 1475-2840